Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus

NCT00175370

Staphylococcal Infections

COMPLETED NA

Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

NCT01786161

MRSA - Methicillin Resistant Staphylococcus Aureus Infection

TERMINATED PHASE4

Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry

NCT02896218

Critically Ill

UNKNOWN

Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

NCT01925066

Pneumonia, Staphylococcal Methicillin-Resistant Staphylococcus Aureus

COMPLETED PHASE2

Swab Testing to Optimize Pneumonia Treatment with Empiric Vancomycin

NCT06272994

Community-acquired Pneumonia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Escherichia Coli Infections Klebsiella Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vancomycin-resistant enterococci and ESBL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients admitted to or transferred to the MICU.
* Patients 18 years of age or older.
* Provide written informed consent.

Exclusion Criteria

* Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.
* Patients who have hypersensitivity to penicillin.
* Any underlying conditions or diseases that will be ultimately fatal within 48 hours.
* Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No